---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011561"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:03:03.943271+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech posts Q2 net income $13.4M; Checkpoint acquisition yields $28M upfront

## Summary
- Checkpoint acquired by Sun Pharma in May; Fortress received ~$28M at close, up to $4.8M CVR, plus 2.5% royalty on UNLOXCYT sales.
- FDA accepted CUTX-101 NDA for priority review; PDUFA goal date September 30, 2025.
- Q2 consolidated net revenue $16.4M ($15.0M from dermatology); net income $13.4M vs net loss $13.3M a year ago.
- Consolidated cash $74.4M as of June 30, up from $57.3M at Dec 31, 2024, boosted by Checkpoint proceeds.
- Emrosi commercial launch underway; payer coverage expanded to 100M U.S. commercial lives as of July 2025.

## SEC filing metadata
- accession: 0001558370-25-011561
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/0001558370-25-011561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837025011561/fbio-20250814x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011561
- JSON: https://secwatch.observer/filing/0001558370-25-011561.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011561.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.